Iridian Asset Management LLC CT grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,228,399 shares of the biopharmaceutical company’s stock after buying an additional 967,923 shares during the quarter. Iridian Asset Management LLC CT owned 6.40% of Halozyme Therapeutics worth $167,680,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cubist Systematic Strategies LLC raised its position in shares of Halozyme Therapeutics by 69.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 22,346 shares of the biopharmaceutical company’s stock valued at $377,000 after buying an additional 9,134 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $21,690,000. Rhumbline Advisers raised its position in shares of Halozyme Therapeutics by 7.0% during the 2nd quarter. Rhumbline Advisers now owns 132,784 shares of the biopharmaceutical company’s stock valued at $2,240,000 after buying an additional 8,703 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 76.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 643,822 shares of the biopharmaceutical company’s stock worth $10,862,000 after purchasing an additional 277,953 shares during the period. Finally, Wells Fargo & Company MN raised its position in Halozyme Therapeutics by 60.3% in the 2nd quarter. Wells Fargo & Company MN now owns 535,697 shares of the biopharmaceutical company’s stock worth $9,038,000 after purchasing an additional 201,507 shares during the period. Hedge funds and other institutional investors own 85.52% of the company’s stock.

A number of research firms recently weighed in on HALO. Cantor Fitzgerald set a $27.00 price objective on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 25th. BidaskClub raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. BMO Capital Markets increased their price objective on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the stock a “market perform” rating in a research report on Wednesday, August 8th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Tuesday, November 13th. Finally, ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 19th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.56.

In other news, major shareholder Randal J. Kirk sold 161,246 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $17.15, for a total transaction of $2,765,368.90. Following the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at $61,094,954.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Randal J. Kirk sold 644,998 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The stock was sold at an average price of $18.08, for a total transaction of $11,661,563.84. Following the transaction, the insider now directly owns 3,562,388 shares in the company, valued at $64,407,975.04. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,000,706 shares of company stock worth $35,509,187. Corporate insiders own 14.10% of the company’s stock.

Halozyme Therapeutics stock opened at $16.13 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.96 and a current ratio of 3.09. Halozyme Therapeutics, Inc. has a 1-year low of $14.33 and a 1-year high of $21.48. The stock has a market capitalization of $2.33 billion, a P/E ratio of 35.84 and a beta of 1.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.04. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. The company had revenue of $25.60 million for the quarter, compared to analyst estimates of $30.42 million. During the same period in the prior year, the company posted $0.02 EPS. The firm’s revenue for the quarter was down 59.8% on a year-over-year basis. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post -0.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Iridian Asset Management LLC CT Acquires 967,923 Shares of Halozyme Therapeutics, Inc. (HALO)” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/11/19/iridian-asset-management-llc-ct-acquires-967923-shares-of-halozyme-therapeutics-inc-halo.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: Balanced Fund

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.